Myeloproliferative Neoplasms News

SAN DIEGO — Pacritinib may provide a “unique survival advantage” for patients with myelofibrosis also exhibiting moderate or severe thrombocythemia, according to data from the PERSIST-2 study, presented at ASH Annual Meeting and Exposition.

In a special scientific session on race and science at ASH Annual Meeting an Exposition, Saad Z. Usmani, MD, MBA, FACP, FRCP, examined clinical trial inclusion from an investigator’s perspective.

SAN DIEGO — Navitoclax added to ruxolitinib led to a significant improvement in spleen volume reduction compared with placebo among patients with untreated myelofibrosis, study results presented at ASH Annual Meeting and Exposition showed.

SAN DIEGO — An international group of researchers developed an artificial intelligence-based algorithm that differentiates prefibrotic primary myelofibrosis from essential thrombocythemia during pathological analysis, study findings showed.

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 9-12 in San Diego.

Three physicians have been elected to serve in leadership roles on ASH’s executive committee.

The combination of pelabresib plus ruxolitinib significantly increased the proportion of patients with myelofibrosis who achieved a clinically meaningful reduction in spleen volume, according to the agent’s manufacturer.

President Joe Biden today announced his intention to appoint oncologist, researcher and educator, W. Kimryn Rathmell, MD, PhD, as director of the NCI.

The FDA approved ivosidenib for treatment of certain adults with relapsed or refractory myelodysplastic syndromes.

The FDA approved momelotinib for treatment of patients with myelofibrosis and anemia regardless of prior myelofibrosis therapy.